Par Drugs And Stock Current Valuation
| PAR Stock | 288.35 4.15 1.42% |
Valuation analysis of Par Drugs And helps investors to measure Par Drugs' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Par Drugs' Cash And Short Term Investments are projected to increase significantly based on the last few years of reporting. The current year's Change In Cash is expected to grow to about 151.3 M, whereas Other Cashflows From Financing Activities is projected to grow to (55.5 M). Fundamental drivers impacting Par Drugs' valuation include:
Price Book 3.6668 | Enterprise Value 3.4 B | Enterprise Value Ebitda 11.9454 | Price Sales 3.4024 | Trailing PE 19.3674 |
Overvalued
Today
Please note that Par Drugs' price fluctuation is very steady at this time. Calculation of the real value of Par Drugs And is based on 3 months time horizon. Increasing Par Drugs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Par stock is determined by what a typical buyer is willing to pay for full or partial control of Par Drugs And. Since Par Drugs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Par Stock. However, Par Drugs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 288.35 | Real 230.91 | Hype 284.61 | Naive 288.34 |
The real value of Par Stock, also known as its intrinsic value, is the underlying worth of Par Drugs And Company, which is reflected in its stock price. It is based on Par Drugs' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Par Drugs' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Par Drugs And helps investors to forecast how Par stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Par Drugs more accurately as focusing exclusively on Par Drugs' fundamentals will not take into account other important factors: Par Drugs And Company Current Valuation Analysis
Par Drugs' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Par Drugs Current Valuation | 3.36 B |
Most of Par Drugs' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Par Drugs And is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Par Drugs And has a Current Valuation of 3.36 B. This is 76.61% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all India stocks is 79.79% higher than that of the company.
Par Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Par Drugs' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Par Drugs could also be used in its relative valuation, which is a method of valuing Par Drugs by comparing valuation metrics of similar companies.Par Drugs is currently under evaluation in current valuation category among its peers.
Par Fundamentals
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 3.36 B | ||||
| Shares Outstanding | 12.3 M | ||||
| Price To Book | 3.67 X | ||||
| Price To Sales | 3.40 X | ||||
| Revenue | 956.4 M | ||||
| Gross Profit | 457.57 M | ||||
| EBITDA | 229.53 M | ||||
| Net Income | 145.01 M | ||||
| Total Debt | 159.79 M | ||||
| Book Value Per Share | 78.69 X | ||||
| Cash Flow From Operations | 202.49 M | ||||
| Earnings Per Share | 14.86 X | ||||
| Number Of Employees | 122 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 3.54 B | ||||
| Total Asset | 1.02 B | ||||
| Retained Earnings | 625.51 M | ||||
| Working Capital | 471.85 M | ||||
| Net Asset | 1.02 B |
About Par Drugs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Par Drugs And's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Par Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Par Drugs And based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Par Stock
Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.